CSI Market
Sign In | Register

Biostax (BTAX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BTAX Annual Cash Flow →
Looking at cash flow data from Biostax through Sep 30 2023 provides insight into Sep 30 2024's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2024)
9 Months 		(Jun 30 2024) (Mar 31 2024) (Dec 31 2023) (Sep 30 2023)
Operating Activities
Income-0.82
Depreciation & amortization0.00
Amortization of Other Assets0.00
Accretion Expense0.05
Impairment of Intangible Assets, Finite-lived0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Stock Warrant Expense-
Stock Issued For Donation-
Stock Issued For Interest-
Stock Issued For Services-
Stock Issued For Legal Settlement-
Stock Issued For Patents And Licenses-
Amortization Of Stock Issued For Prepaid Services-
Accrued Liabilities-
Other Than Temporary Impairment Losses Investments Availableforsale Securities-
Loss On Settlement Of Debt And Accounts Payable-
Stock Warrant Expense-
Adjustments To Additional Paid In Capital Other-
Stock Issued For Loan Expenses And Interest-
Recovery Of Amount Due-
Derivative Gain Loss On Derivative Net-
Change In Market Value Of Equity Securities-
Gain On Issuance Of Forte License-
Common Stock Issued For Extension Of Patent And License Agreement-
Loss Gain On Derivative Liability-
Other Nonoperating Income Expense-0.06
Increase Decrease In License Fees Payable-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Accounts Payable0.53
Accrued Expense0.27
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Deposit Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-0.04
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Purchase Of Penn State License-
Purchase Of License-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.01
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Exercise Of Stock Options-
Proceeds From Sale Of Stock-
Payments Made On Patent Liability-
Cash Flows From Discontinued Operations-
Net Cash Provided By Used In Operating Activities-
Proceeds From Sale Of Common Stock And Exercise Of Warrants-
Proceeds From Sale Of Stock And Exercise Of Warrants-
Proceeds From Undocumented Investor Advances-
Proceeds From Investor Advances-
Advances From Related Party-
Repayment Of Advances From Related Party-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.01
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.04
Total Cash Flow-0.03
4 historic quarters locked

Sign in to unlock the full Biostax cash flow history.

Sign In Create Free Account

About Biostax Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001376474-25-000322

Figures are derived from filed reports and may be restated. Historical data is subject to revision.